Journal
PEDIATRIC NEPHROLOGY
Volume 35, Issue 11, Pages 2113-2120Publisher
SPRINGER
DOI: 10.1007/s00467-020-04622-3
Keywords
Children; Pyelonephritis; UTI; Dexamethasone; Clinical trials; DMSA; Kidneys
Categories
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [R01DK087870]
Ask authors/readers for more resources
Background To evaluate the efficacy of adjuvant systemic corticosteroids in reducing kidney scarring. A previous study suggested that use of adjuvant systemic corticosteroids reduces kidney scarring in children radiologically confirmed to have extensive pyelonephritis. Efficacy of corticosteroids for children with febrile urinary tract infection (UTI) has not been studied. Methods Children aged 2 months to 6 years with their first febrile UTI were randomized to corticosteroids or placebo for 3 days (both arms received antimicrobial therapy); kidney scarring was assessed using(99m)Tc-dimercaptosuccinic acid kidney scan 5-24 months after the initial UTI. Results We randomized 546 children of which 385 had a UTI and 254 had outcome kidney scans (instead of the 320 planned). Rates of kidney scarring were 9.8% (12/123) and 16.8% (22/131) in the corticosteroid and placebo groups, respectively (p = 0.16), corresponding to an absolute risk reduction of 5.9% (95% confidence interval: - 2.2, 14.1). Conclusion While children randomized to adjuvant corticosteroids tended to develop fewer kidney scars than children who were randomized to receive placebo, a statistically significant difference was not achieved. However, the study was limited by not reaching its intended sample size.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available